XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.3

Significant agreements - Genentech Collaboration Agreement (Details) $ in Thousands		1 Months Ended		3 Months Ended			9 Months Ended		12 Months Ended
	Feb. 21, 2020 USD ($) item	Dec. 31, 2022 USD ($)	Nov. 30, 2021 USD ($)	Sep. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) item	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Jun. 30, 2023 USD ($)	Oct. 31, 2021 USD ($)	Mar. 31, 2021 USD ($)
Significant agreements.
Deferred revenue		$ 61,873		$ 109,191			$ 109,191		$ 135,194
Collaboration revenues				2,676		$ 5,352	31,567	$ 21,645
Genentech
Significant agreements.
Number of potential development candidates | item	4
Upfront cash payment	$ 30,000
Number of immuno oncology targets | item	2
Additional number of immuno oncology targets | item	2
Expansion fee	$ 10,000
Milestone payments, receivable												$ 2,000
Transaction price	31,000			33,000			33,000					$ 33,000
Deferred revenue		39,308		15,904			15,904		29,104
Collaboration revenues				566		$ 1,364	$ 13,889	$ 11,112
Genentech | Royalty
Significant agreements.
Number of years over which royalty is payable							10 years
Genentech | Maximum
Significant agreements.
Milestone payments, receivable	200,000
Genentech | Development milestone | Maximum
Significant agreements.
Milestone payments, receivable	65,000
Genentech | Regulatory milestone | Maximum
Significant agreements.
Milestone payments, receivable	$ 135,000
Genentech | Collaboration Program 1 Performance Obligation
Significant agreements.
Transaction price				4,019			$ 4,019
Genentech | Collaboration Program 2 Performance Obligation
Significant agreements.
Transaction price				8,037			8,037
Genentech | Specified Targeting Arm Material Right Arm Program One
Significant agreements.
Number of initial collaboration programs exercised | item	1
Option fee for development and exploitation rights	$ 1,000
Milestone payments, receivable	$ 1,000
Transaction price				352			$ 352
Genentech | Two material rights associated with the LSR Go Option for Collaboration Programs One And Two
Significant agreements.
Number of collaboration programs | item	2						2
Number of expansion option collaboration programs | item							2
Transaction price				12,400			$ 12,400
Genentech | Material rights for associated and limited substitution rights
Significant agreements.
Transaction price				1,187			1,187
Deferred revenue		700
Genentech | Two material rights for Expansion Options
Significant agreements.
Number of expansion option collaboration programs | item	2
Transaction price				$ 7,005			$ 7,005
Genentech | Collaboration Program One and Two Performance Obligation
Significant agreements.
Material rights exercise period							4 years
Genentech | Collaboration Program One and Two Performance Obligation | Maximum
Significant agreements.
Regulatory, and initial commercialization milestones, payments receivable	$ 200,000
Period over which performance obligations will be performed							3 years
Genentech | Collaboration Program One and Two Performance Obligation | Minimum
Significant agreements.
Period over which performance obligations will be performed							2 years
Genentech | Material rights associated with the LSR Go Option for Collaboration Programs One
Significant agreements.
Deferred revenue										$ 6,000
Genentech | Collaboration Program 3 Performance Obligation
Significant agreements.
Expansion fee			$ 10,000
Milestone payments, receivable											$ 1,000
Transaction price											11,000
Material rights											$ 3,500
Amount of estimate of variable consideration		2,000
Collaboration revenues		$ 8,400			$ 10,400
Revenue recognized					$ 7,500
Genentech | Collaboration Program 3 Performance Obligation | Maximum
Significant agreements.
Period over which performance obligations will be performed		3 years
Genentech | Collaboration Program 3 Performance Obligation | Minimum
Significant agreements.
Period over which performance obligations will be performed		2 years
Genentech | Collaboration Program 4 Performance Obligation
Significant agreements.
Transaction price									10,000
Deferred revenue		$ 100
Material rights									3,500
Collaboration revenues									$ 5,300
Genentech | Material rights associated with the LSR Go Option for Collaboration Programs Three
Significant agreements.
Deferred revenue		7,400
Genentech | Material rights associated with the LSR Go Option for Collaboration Programs Four
Significant agreements.
Deferred revenue		$ 7,400

X

- Definition

Additional number of immuno oncology targets.

+ References

No definition available.

+ Details

Name:	bcyc_AdditionalNumberOfImmunoOncologyTargets
Namespace Prefix:	bcyc_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Amount of Regulatory, and initial commercialization milestones payments receivable by the entity.

+ References

No definition available.

+ Details

Name:	bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable
Namespace Prefix:	bcyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of regulatory, development, commercialization or sales milestone payments, receivable by the entity.

+ References

No definition available.

+ Details

Name:	bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable
Namespace Prefix:	bcyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of material rights under collaboration program.

+ References

No definition available.

+ Details

Name:	bcyc_CollaborationProgramAmountOfMaterialRights
Namespace Prefix:	bcyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The amount of upfront cash payment received from collaborative arrangement.

+ References

No definition available.

+ Details

Name:	bcyc_CollaborativeArrangementUpfrontCashPaymentReceived
Namespace Prefix:	bcyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of estimated variable consideration no longer constrained.

+ References

No definition available.

+ Details

Name:	bcyc_EstimatedVariableConsiderationNoLongerConstrained
Namespace Prefix:	bcyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of expansion fee to per additional collaboration program.

+ References

No definition available.

+ Details

Name:	bcyc_ExpansionFeePerAdditionalCollaborationProgram
Namespace Prefix:	bcyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The duration of material rights exercised or expired.

+ References

No definition available.

+ Details

Name:	bcyc_MaterialRightsExerciseOrExpiryTerm
Namespace Prefix:	bcyc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the number of collaboration programs.

+ References

No definition available.

+ Details

Name:	bcyc_NumberOfCollaborationPrograms
Namespace Prefix:	bcyc_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the number of expansion option programs (Dev Go option).

+ References

No definition available.

+ Details

Name:	bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo
Namespace Prefix:	bcyc_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of immuno oncology targets.

+ References

No definition available.

+ Details

Name:	bcyc_NumberOfImmunoOncologyTargets
Namespace Prefix:	bcyc_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Represents number of initial Genentech Collaboration Programs exercised.

+ References

No definition available.

+ Details

Name:	bcyc_NumberOfInitialCollaborationPrograms
Namespace Prefix:	bcyc_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Number of Potential development candidates.

+ References

No definition available.

+ Details

Name:	bcyc_NumberOfPotentialDevelopmentCandidates
Namespace Prefix:	bcyc_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Represents number of years over which royalty is payable.

+ References

No definition available.

+ Details

Name:	bcyc_NumberOfYearsOverWhichRoyaltyIsPayable
Namespace Prefix:	bcyc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount to be paid upon exercise of an option by the customer.

+ References

No definition available.

+ Details

Name:	bcyc_OptionFeeForDevelopmentAndExploitationRights
Namespace Prefix:	bcyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents period over which performance obligations will be performed.

+ References

No definition available.

+ Details

Name:	bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed
Namespace Prefix:	bcyc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of allocated determined transaction price under revenue recognition arrangement.

+ References

No definition available.

+ Details

Name:	bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice
Namespace Prefix:	bcyc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	bcyc_AchievementOfMilestoneAxis=bcyc_DevelopmentMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	bcyc_AchievementOfMilestoneAxis=bcyc_RegulatoryMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationOnePerformanceObligationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationTwoPerformanceObligationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsForExpansionOptionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationPerformanceOneAndTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationProgramThreePerformanceObligationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationProgram4PerformanceObligationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: